Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with that of Orthogonal Methods for Detecting Targetable Genetic Alterations
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최윤지 | - |
dc.contributor.author | 최정윤 | - |
dc.contributor.author | 김주원 | - |
dc.contributor.author | 임아름 | - |
dc.contributor.author | 이영우 | - |
dc.contributor.author | 장원진 | - |
dc.contributor.author | 이수현 | - |
dc.contributor.author | 성재숙 | - |
dc.contributor.author | 정희준 | - |
dc.contributor.author | 이종원 | - |
dc.contributor.author | 강은주 | - |
dc.contributor.author | 김정선 | - |
dc.contributor.author | 임태규 | - |
dc.contributor.author | 김혜숙 | - |
dc.contributor.author | 김유정 | - |
dc.contributor.author | 안미선 | - |
dc.contributor.author | 김영생 | - |
dc.contributor.author | 박지현 | - |
dc.contributor.author | 임승택 | - |
dc.contributor.author | 조성심 | - |
dc.contributor.author | 조장호 | - |
dc.contributor.author | 신상원 | - |
dc.contributor.author | 박경화 | - |
dc.contributor.author | 김열홍 | - |
dc.date.accessioned | 2022-02-11T18:40:37Z | - |
dc.date.available | 2022-02-11T18:40:37Z | - |
dc.date.created | 2022-01-20 | - |
dc.date.issued | 2022-01 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/135366 | - |
dc.description.abstract | Purpose K-MASTER project is a Korean national precision medicine platform that screened actionable mutations by analyzing next-generation sequencing (NGS) of solid tumor patients. We compared gene analyses between NGS panel from the K-MASTER project and orthogonal methods. Materials and Methods Colorectal, breast, non–small cell lung, and gastric cancer patients were included. We compared NGS results from K-MASTER projects with those of non-NGS orthogonal methods (KRAS, NRAS, and BRAF mutations in colorectal cancer [CRC]; epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK] fusion, and reactive oxygen species 1 [ROS1] fusion in non–small cell lung cancer [NSCLC], and Erb-B2 receptor tyrosine kinase 2 (ERBB2) positivity in breast and gastric cancers). Results In the CRC cohort (n=225), the sensitivity and specificity of NGS were 87.4% and 79.3% (KRAS); 88.9% and 98.9% (NRAS); and 77.8% and 100.0% (BRAF), respectively. In the NSCLC cohort (n=109), the sensitivity and specificity of NGS for EGFR were 86.2% and 97.5%, respectively. The concordance rate for ALK fusion was 100%, but ROS1 fusion was positive in only one of three cases that were positive in orthogonal tests. In the breast cancer cohort (n=260), ERBB2 amplification was detected in 45 by NGS. Compared with orthogonal methods that integrated immunohistochemistry and in situ hybridization, sensitivity and specificity were 53.7% and 99.4%, respectively. In the gastric cancer cohort (n=64), ERBB2 amplification was detected in six by NGS. Compared with orthogonal methods, sensitivity and specificity were 62.5% and 98.2%, respectively. Conclusion The results of the K-MASTER NGS panel and orthogonal methods showed a different degree of agreement for each genetic alteration, but generally showed a high agreement rate. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | 대한암학회 | - |
dc.title | Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with that of Orthogonal Methods for Detecting Targetable Genetic Alterations | - |
dc.title.alternative | Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with that of Orthogonal Methods for Detecting Targetable Genetic Alterations | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 최윤지 | - |
dc.identifier.doi | 10.4143/crt.2021.218 | - |
dc.identifier.scopusid | 2-s2.0-85123582863 | - |
dc.identifier.wosid | 000788852400004 | - |
dc.identifier.bibliographicCitation | Cancer Research and Treatment, v.54, no.1, pp.30 - 39 | - |
dc.relation.isPartOf | Cancer Research and Treatment | - |
dc.citation.title | Cancer Research and Treatment | - |
dc.citation.volume | 54 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 30 | - |
dc.citation.endPage | 39 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002802589 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordAuthor | High-throughput nucleotide sequencing | - |
dc.subject.keywordAuthor | Pathology | - |
dc.subject.keywordAuthor | Molecular | - |
dc.subject.keywordAuthor | Precision medicine | - |
dc.subject.keywordAuthor | Targetable gene alteration | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.